Compare GSK plc (GSK) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs ProShares UltraPro S&P500 — how do they compare? GSK plc trades at $52.8 (market cap $101.34B), while ProShares UltraPro S&P500 trades at $144.16. The key difference: GSK plc pays a 3.49% dividend while ProShares UltraPro S&P500 pays none, and ProShares UltraPro S&P500 is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | UPRO | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $150.93 |
52-Week Low | $36.20 | $89.29 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
UPRO trades at $145.25, up 0.67% on the day, with a bullish technical signal driven by strong moving average alignment. The stock exhibits neutral oscillators but faces key resistance near $147. Recent news highlights S&P 500 momentum, with earnings season and inflation data influencing near-term direction.
The outlook remains cautiously optimistic given bullish technicals and positive market sentiment, though stretched valuations and macroeconomic risks pose headwinds. Investors should weigh strong institutional support against potential volatility from Fed policy and earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
